{"slug":"pfizer","name":"화이자","name_en":"Pfizer Inc.","ticker":"PFE","updated_at":"2026-09-24T05:25:43.783123+00:00","canonical":"https://valuechain.wiki/pfizer","citable":"밸류체인 그래프 기준 화이자의 직접 연결 기업은 6곳(관계 기준 공급 3·매출 3)이고, 사슬을 2차까지 넓히면 11곳에 닿는다. 링크의 근거 출처는 6건이며 그중 1차공시가 2건이다 (valuechain.wiki, 2026-09-24 기준).","citable_en":"Per the valuechain.wiki graph, Pfizer Inc. is directly linked to 6 companies (3 supply, 3 revenue relationships) and reaches 11 companies within two hops; the links are backed by 6 dated sources, 2 of them primary filings (as of 2026-09-24).","kicker":"글로벌 혁신의약품사","kicker_en":"Global innovative biopharma","lead":"화이자는 처방의약품과 백신을 개발해 대형 도매상, 의료기관, 정부 등에 판매한다. 생산 위탁사와 공동개발 파트너에 비용을 지급하고, 인수로 비만·대사질환과 항암제 파이프라인을 보강한다.","lead_en":"Pfizer develops prescription medicines and vaccines and sells them through major wholesalers and directly to healthcare providers and governments. It pays contract manufacturers and collaboration partners, while using acquisitions to expand its obesity, cardiometabolic and oncology pipelines.","categories":[{"key":"pharma-biotech","ko":"제약·바이오텍","en":"Pharmaceuticals & Biotechnology","theme":"life-sciences","theme_ko":"바이오·헬스","theme_en":"Biopharma & Life Sciences","theme_kind":"sector","primary":true},{"key":"oncology-adc","ko":"항암·ADC","en":"Oncology & ADCs","theme":"life-sciences","theme_ko":"바이오·헬스","theme_en":"Biopharma & Life Sciences","theme_kind":"sector","primary":false}],"segments":{"parts":[{"name":"바이오파마","note":"단일 보고부문으로 Primary Care, Specialty Care, Oncology 상업 사업을 포함한다."},{"name":"기타","note":"Pfizer CentreOne 계약생산과 기타 비바이오파마 수익을 포함한다."}],"total":"FY2025 총매출 62,579,000,000 USD (PFIZER INC 2025 Form 10-K, 2026-02-26)","track":"C"},"segments_en":{"parts":[{"name":"Biopharma","note":"The single reportable segment, including the Primary Care, Specialty Care and Oncology commercial businesses."},{"name":"Other","note":"Includes Pfizer CentreOne contract manufacturing and other non-Biopharma revenue."}],"total":"FY2025 total revenue USD 62,579,000,000 (PFIZER INC 2025 Form 10-K, 2026-02-26)"},"returns_yearly":{"2021":66.7,"2022":-10.4,"2023":-41.3,"2024":-2.2,"2025":0.6,"2026":20.2},"return_asof":"2026-09-04","value_chain":{"leading":[{"slug":"unitedhealth-group","name":"유나이티드헬스 그룹","name_en":"UnitedHealth Group Incorporated","tier":3,"returns_yearly":{"2021":45.2,"2022":6.9,"2023":0.8,"2024":-2.4,"2025":-33.1,"2026":21.9}},{"slug":"elevance-health","name":"엘레반스 헬스","name_en":"Elevance Health, Inc.","tier":3,"returns_yearly":{"2021":46.1,"2022":11.8,"2023":-6.9,"2024":-20.7,"2025":-3.1,"2026":17.4}},{"slug":"cvs-health","name":"CVS 헬스","name_en":"CVS Health","tier":2,"returns_yearly":{"2021":54.9,"2022":-7.6,"2023":-12.5,"2024":-40.8,"2025":84.3,"2026":24.7}},{"slug":"walmart","name":"Walmart Inc","name_en":"Walmart Inc","tier":2,"returns_yearly":{"2021":2,"2022":-0.5,"2023":12.9,"2024":74,"2025":24.5,"2026":0.6}},{"slug":"cardinal-health","name":"카디널 헬스","name_en":"Cardinal Health, Inc.","tier":1,"returns_yearly":{"2021":-0.4,"2022":54.1,"2023":34.1,"2024":19,"2025":76.3,"2026":21.1}},{"slug":"mckesson","name":"맥케슨","name_en":"McKesson Corporation","tier":1,"returns_yearly":{"2021":44.2,"2022":51.8,"2023":24.1,"2024":23.7,"2025":44.5,"2026":14.8}},{"slug":"cencora","name":"센코라","name_en":"Cencora, Inc.","tier":1,"returns_yearly":{"2021":44.1,"2022":26.3,"2023":25.3,"2024":10.4,"2025":51.5,"2026":-1.4}}],"benefiting":[{"slug":"agilent-technologies","name":"애질런트 테크놀로지스","name_en":"Agilent Technologies, Inc.","tier":1,"returns_yearly":{"2021":35.5,"2022":-5.5,"2023":-6.4,"2024":-2.7,"2025":1.9,"2026":11.5}},{"slug":"mettler-toledo","name":"메틀러 토레도","name_en":"Mettler-Toledo International Inc.","tier":1,"returns_yearly":{"2021":48.9,"2022":-14.8,"2023":-16.1,"2024":0.9,"2025":13.9,"2026":-3.5}},{"slug":"samsung-biologics","name":"삼성바이오로직스","name_en":"Samsung Biologics","tier":1,"returns_yearly":{"2021":-6.8,"2022":8.6,"2023":5.8,"2024":28.7,"2025":5,"2026":-30.1}},{"slug":"samsung-e-a","name":"삼성E&A","name_en":"Samsung E&A","tier":2,"returns_yearly":{"2021":74.5,"2022":20,"2023":-13.7,"2024":-15.9,"2025":76.7,"2026":56.7}},{"slug":"amazon","name":"아마존","name_en":"Amazon","tier":2,"returns_yearly":{"2021":2.4,"2022":-49.6,"2023":80.9,"2024":44.4,"2025":5.2,"2026":12}},{"slug":"danaher","name":"다나허","name_en":"Danaher Corporation","tier":2,"returns_yearly":{"2021":48.6,"2022":-19,"2023":-1.2,"2024":-0.3,"2025":0.4,"2026":-3.4}},{"slug":"sandisk","name":"샌디스크","name_en":"SanDisk","tier":3,"returns_yearly":{"2026":633}},{"slug":"seagate","name":"Seagate","name_en":"Seagate Technology","tier":3,"returns_yearly":{"2021":87.5,"2022":-51.4,"2023":69.1,"2024":4.1,"2025":225.3,"2026":209.1}},{"slug":"marvell","name":"Marvell","name_en":"Marvell","tier":3,"returns_yearly":{"2021":84.6,"2022":-57.5,"2023":63.7,"2024":83.8,"2025":-22.8,"2026":163.4}},{"slug":"astera-labs","name":"Astera Labs","name_en":"Astera Labs","tier":3,"returns_yearly":{"2025":25.6,"2026":105.7}},{"slug":"wiwynn","name":"Wiwynn","name_en":"Wiwynn","tier":3,"returns_yearly":{"2021":24.7,"2022":-22.3,"2023":206.4,"2024":3.5,"2025":64.4,"2026":92.3}},{"slug":"sk-hynix","name":"SK하이닉스","name_en":"SK hynix","tier":3,"returns_yearly":{"2021":-0.4,"2022":-25.6,"2023":53.9,"2024":48.6,"2025":361.1,"2026":85.3}},{"slug":"corning","name":"Corning","name_en":"Corning","tier":3,"returns_yearly":{"2021":5.9,"2022":-11.6,"2023":-1.2,"2024":60.6,"2025":87.8,"2026":77.2}},{"slug":"ge-vernova","name":"GE Vernova","name_en":"GE Vernova","tier":3,"returns_yearly":{"2025":99,"2026":54}},{"slug":"tsmc","name":"TSMC","name_en":"TSMC","tier":3,"returns_yearly":{"2021":12.1,"2022":-36.7,"2023":42.3,"2024":92.6,"2025":55.9,"2026":50.3}},{"slug":"occidental-petroleum","name":"옥시덴탈 페트롤리엄","name_en":"Occidental Petroleum","tier":3,"returns_yearly":{"2021":67.7,"2022":119.1,"2023":-4.1,"2024":-15.9,"2025":-14.9,"2026":48.2}},{"slug":"arista","name":"Arista Networks","name_en":"Arista Networks","tier":3,"returns_yearly":{"2021":97.9,"2022":-15.6,"2023":94.1,"2024":87.7,"2025":18.5,"2026":47.9}},{"slug":"caterpillar","name":"Caterpillar","name_en":"Caterpillar","tier":3,"returns_yearly":{"2021":16,"2022":18.6,"2023":25.9,"2024":24.7,"2025":60.3,"2026":40.6}},{"slug":"alchip","name":"알칩","name_en":"Alchip Technologies","tier":3,"returns_yearly":{"2021":14.3,"2022":-8.7,"2023":365.1,"2024":-18.9,"2025":0.8,"2026":40.1}},{"slug":"fedex","name":"페덱스","name_en":"FedEx","tier":3,"returns_yearly":{"2021":0.7,"2022":-31.6,"2023":49.1,"2024":13.5,"2025":5.1,"2026":39.6}},{"slug":"ciena","name":"Ciena","name_en":"Ciena","tier":3,"returns_yearly":{"2021":45.6,"2022":-33.8,"2023":-11.7,"2024":88.4,"2025":175.8,"2026":37.3}},{"slug":"globalstar","name":"글로벌스타","name_en":"Globalstar","tier":3,"returns_yearly":{"2021":241.2,"2022":14.7,"2023":45.9,"2024":6.7,"2025":96.6,"2026":37.3}},{"slug":"jabil","name":"자빌","name_en":"Jabil","tier":3,"returns_yearly":{"2021":66.4,"2022":-2.5,"2023":87.4,"2024":13.3,"2025":58.7,"2026":36.3}},{"slug":"eaton","name":"Eaton","name_en":"Eaton","tier":3,"returns_yearly":{"2021":46.7,"2022":-7.2,"2023":56.2,"2024":39.5,"2025":-2.8,"2026":36}},{"slug":"digital-realty","name":"Digital Realty","name_en":"Digital Realty","tier":3,"returns_yearly":{"2021":30.7,"2022":-41,"2023":39.9,"2024":35.9,"2025":-10.1,"2026":23.4}},{"slug":"nvidia","name":"NVIDIA","name_en":"NVIDIA","tier":3,"returns_yearly":{"2021":125.5,"2022":-50.3,"2023":239,"2024":171.2,"2025":38.9,"2026":23.2}},{"slug":"celestica","name":"Celestica","name_en":"Celestica","tier":3,"returns_yearly":{"2021":37.9,"2022":1.3,"2023":159.8,"2024":215.2,"2025":220.3,"2026":22.5}},{"slug":"quanta","name":"Quanta","name_en":"Quanta Computer","tier":3,"returns_yearly":{"2021":22.2,"2022":-12.8,"2023":254.5,"2024":12.7,"2025":8.9,"2026":21.2}},{"slug":"credo","name":"크레도","name_en":"Credo Technology","tier":3,"returns_yearly":{"2023":46.3,"2024":245.2,"2025":114.1,"2026":18.5}},{"slug":"abb","name":"ABB","name_en":"ABB","tier":3,"returns_yearly":{"2021":23.9,"2022":7.3,"2023":18.9,"2024":39,"2025":36.1,"2026":18.4}},{"slug":"church-dwight","name":"처치 앤 드와이트","name_en":"Church & Dwight Co., Inc.","tier":3,"returns_yearly":{"2021":18.9,"2022":-20.4,"2023":18.7,"2024":12,"2025":-18.9,"2026":18.1}},{"slug":"foxconn","name":"Foxconn","name_en":"Foxconn (Hon Hai)","tier":3,"returns_yearly":{"2021":-5.1,"2022":2.8,"2023":7.8,"2024":80.1,"2025":26.9,"2026":16.3}},{"slug":"norfolk-southern","name":"노퍽 서던","name_en":"Norfolk Southern","tier":3,"returns_yearly":{"2021":27.3,"2022":-15.6,"2023":-1.6,"2024":1.6,"2025":25.6,"2026":15.6}},{"slug":"colgate-palmolive","name":"콜게이트파몰리브","name_en":"Colgate-Palmolive Company","tier":3,"returns_yearly":{"2021":2.1,"2022":-5.4,"2023":3.8,"2024":16.6,"2025":-11,"2026":14.4}},{"slug":"entergy","name":"엔터지","name_en":"Entergy","tier":3,"returns_yearly":{"2021":17.1,"2022":3.6,"2023":-6.1,"2024":56,"2025":25.3,"2026":13.2}},{"slug":"schneider-electric","name":"Schneider Electric","name_en":"Schneider Electric","tier":3,"returns_yearly":{"2021":25.9,"2022":1.6,"2023":25.8,"2024":36.1,"2025":0.5,"2026":11.7}},{"slug":"cummins","name":"Cummins","name_en":"Cummins","tier":3,"returns_yearly":{"2021":-1.7,"2022":14.1,"2023":1.7,"2024":48.9,"2025":49.4,"2026":11}},{"slug":"united-parcel-service","name":"유나이티드 파셀 서비스","name_en":"United Parcel Service, Inc.","tier":3,"returns_yearly":{"2021":30,"2022":-16.2,"2023":-6,"2024":-15.9,"2025":-15.9,"2026":8}},{"slug":"procter-gamble","name":"Procter & Gamble","name_en":"Procter & Gamble","tier":3,"returns_yearly":{"2021":20.5,"2022":-5,"2023":-0.9,"2024":17.3,"2025":-12.3,"2026":4.5}},{"slug":"ameren","name":"아메렌","name_en":"Ameren Corporation","tier":3,"returns_yearly":{"2021":17.1,"2022":2.5,"2023":-16.1,"2024":27.5,"2025":15.3,"2026":4.5}},{"slug":"omnicom-group","name":"옴니콤 그룹","name_en":"Omnicom Group Inc.","tier":3,"returns_yearly":{"2021":21.9,"2022":15.7,"2023":9.6,"2024":2.5,"2025":-2.6,"2026":4.4}},{"slug":"talen-energy","name":"Talen Energy","name_en":"Talen Energy","tier":3,"returns_yearly":{"2024":214.8,"2025":86.1,"2026":1}},{"slug":"est-e-lauder-companies","name":"에스티 로더","name_en":"The Estée Lauder Companies Inc.","tier":3,"returns_yearly":{"2021":40,"2022":-32.3,"2023":-40.1,"2024":-47.6,"2025":42.1,"2026":0.2}},{"slug":"amorepacific","name":"아모레퍼시픽","name_en":"Amorepacific","tier":3,"returns_yearly":{"2021":-30.1,"2022":-5.7,"2023":-18.4,"2024":9.9,"2025":8.2,"2026":-1.2}},{"slug":"exelon","name":"엑셀론","name_en":"Exelon","tier":3,"returns_yearly":{"2021":41.5,"2022":8.3,"2023":-14,"2024":9.2,"2025":20,"2026":-1.5}},{"slug":"vistra","name":"Vistra","name_en":"Vistra","tier":3,"returns_yearly":{"2021":19.6,"2022":5.1,"2023":70.7,"2024":261.5,"2025":17.7,"2026":-7.2}},{"slug":"fabrinet","name":"Fabrinet","name_en":"Fabrinet","tier":3,"returns_yearly":{"2021":52.7,"2022":8.2,"2023":48.4,"2024":15.5,"2025":107.1,"2026":-10.5}},{"slug":"ionq","name":"IonQ","name_en":"IonQ","tier":3,"returns_yearly":{"2022":-79.3,"2023":259.1,"2024":237.1,"2025":7.4,"2026":-11.9}},{"slug":"abbott-laboratories","name":"애보트","name_en":"Abbott Laboratories","tier":3,"returns_yearly":{"2021":30.5,"2022":-20.7,"2023":2.3,"2024":4.8,"2025":12.9,"2026":-19}},{"slug":"qubt","name":"Quantum Computing Inc","name_en":"Quantum Computing Inc","tier":3,"returns_yearly":{"2021":-75.8,"2022":-55.7,"2023":-39.5,"2024":1712.7,"2025":-38,"2026":-27.5}},{"slug":"rigetti","name":"Rigetti Computing","name_en":"Rigetti Computing","tier":3,"returns_yearly":{"2022":-92.9,"2023":35.1,"2024":1449.2,"2025":45.2,"2026":-31.4}},{"slug":"ecopro-hn","name":"에코프로에이치엔","name_en":"Ecopro HN","tier":3,"returns_yearly":{"2022":4.6,"2023":17,"2024":-47.7,"2025":38,"2026":-38.7}},{"slug":"nike","name":"Nike","name_en":"Nike","tier":3,"returns_yearly":{"2021":18.7,"2022":-29,"2023":-6,"2024":-29.1,"2025":-13.8,"2026":-44.1}},{"slug":"d-wave","name":"D-Wave Quantum","name_en":"D-Wave Quantum","tier":3,"returns_yearly":{"2022":-85.3,"2023":-38.9,"2024":854.5,"2025":211.3,"2026":-44.3}},{"slug":"anthropic","name":"Anthropic","name_en":"Anthropic","tier":3,"returns_yearly":null},{"slug":"cerebras","name":"Cerebras","name_en":"Cerebras Systems","tier":3,"returns_yearly":null},{"slug":"arianegroup","name":"아리안그룹","name_en":"ArianeGroup","tier":3,"returns_yearly":null}],"analysis":"글로벌 혁신의약품사 기업. 2026년 +20.2%다. 본주(+20.2%)와 공급단(평균 -17.1%)이 같은 보폭으로 움직인다.","analysis_en":"Pfizer Inc. operates across Global innovative biopharma. It is +20.2% in 2026. The stock (+20.2%) and its supply side (avg -17.1%) are moving in step. It pays contract manufacturers and collaboration partners, while using acquisitions to expand its obesity, cardiometabolic and oncology pipelines.","analysis_asof":"2026-09-04"},"edges":[{"direction":"investment","counterparty":"멧세라","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2026-02-26","basis":"멧세라 인수 이전대가의 총 공정가치","value":8000000000,"period":"2025-11-13","basis_en":"Total fair value of consideration transferred for the Metsera acquisition","qualifier":null},"note":"화이자는 2025년 11월 비만·심혈관대사질환 신약을 개발하는 멧세라를 인수했다. 이전대가에는 조건부가치권과 인수 전 근무 관련 주식보상이 포함됐다.","note_en":"Pfizer acquired obesity and cardiometabolic drug developer Metsera in November 2025. The consideration included contingent value rights and employee stock awards related to pre-acquisition service.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm","title":"PFIZER INC 2025 사업보고서(Form 10-K)","title_en":"PFIZER INC 2025 Form 10-K","excerpt":"화이자는 멧세라 인수 이전대가의 총 공정가치를 80억 달러로 공시했다.","excerpt_en":"The total fair value of the consideration transferred was $8.0 billion."}]},{"direction":"cost","counterparty":"바이오엔테크","counterparty_slug":null,"confidence":"high","metric":{"type":"amount","unit":"USD","as_of":"2026-02-26","basis":"코미나티 총이익 배분과 관련해 바이오엔테크에 지급할 미지급액","value":911000000,"period":"2025-12-31","basis_en":"Amount payable to BioNTech for the Comirnaty gross profit split","qualifier":null},"note":"화이자는 코미나티 공동사업의 총이익을 바이오엔테크와 나눈다. 2025년 말 화이자가 바이오엔테크에 지급할 미지급액이 공시됐다.","note_en":"Pfizer shares Comirnaty gross profit with BioNTech. Pfizer disclosed the amount payable to BioNTech at the end of 2025.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-03-10","url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm","title":"BioNTech SE 2025 사업보고서(Form 20-F)","title_en":"BioNTech SE 2025 Form 20-F","excerpt":"바이오엔테크는 화이자와 백신 상업화 총이익 및 배송비를 균등하게 나누는 계약이라고 공시했다.","excerpt_en":"We and Pfizer will share the gross profits from commercializing a vaccine evenly, as well as the costs for shipping."},{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm","title":"PFIZER INC 2025 사업보고서(Form 10-K)","title_en":"PFIZER INC 2025 Form 10-K","excerpt":"화이자는 2025년 말 코미나티 총이익 배분 관련 바이오엔테크 미지급액을 9억1,100만 달러로 공시했다.","excerpt_en":"Amounts payable to BioNTech for the gross profit split for Comirnaty totaled $911 million as of December 31, 2025."}]},{"direction":"revenue","counterparty":"맥케슨","counterparty_slug":"mckesson","confidence":"high","metric":{"type":"revenue_share","unit":"percent","as_of":"2026-02-26","basis":"맥케슨에서 발생한 화이자 FY2025 총매출 비중","value":25,"period":"FY2025","basis_en":"Share of Pfizer FY2025 total revenue generated from McKesson","qualifier":null},"note":"맥케슨은 화이자의 가장 큰 미국 도매상 고객이다. FY2025 화이자 총매출에서 차지한 비중이 전년보다 높아졌다.","note_en":"McKesson is Pfizer's largest U.S. wholesaler customer. Its share of Pfizer's total revenue increased in FY2025 from the prior year.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm","title":"PFIZER INC 2025 사업보고서(Form 10-K)","title_en":"PFIZER INC 2025 Form 10-K","excerpt":"10-K는 2025년 맥케슨에서 발생한 매출이 총매출의 25%라고 공시했다.","excerpt_en":"McKesson, Inc. 25%."}]},{"direction":"revenue","counterparty":"센코라","counterparty_slug":"cencora","confidence":"high","metric":{"type":"revenue_share","unit":"percent","as_of":"2026-02-26","basis":"센코라에서 발생한 화이자 FY2025 총매출 비중","value":16,"period":"FY2025","basis_en":"Share of Pfizer FY2025 total revenue generated from Cencora","qualifier":null},"note":"센코라는 화이자의 두 번째로 큰 미국 도매상 고객이다. FY2025 화이자 총매출의 의미 있는 비중을 차지했다.","note_en":"Cencora is Pfizer's second-largest U.S. wholesaler customer and accounted for a material share of FY2025 total revenue.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm","title":"PFIZER INC 2025 사업보고서(Form 10-K)","title_en":"PFIZER INC 2025 Form 10-K","excerpt":"10-K는 2025년 센코라에서 발생한 매출이 총매출의 16%라고 공시했다.","excerpt_en":"Cencora, Inc. 16%."}]},{"direction":"revenue","counterparty":"카디널 헬스","counterparty_slug":"cardinal-health","confidence":"high","metric":{"type":"revenue_share","unit":"percent","as_of":"2026-02-26","basis":"카디널 헬스에서 발생한 화이자 FY2025 총매출 비중","value":13,"period":"FY2025","basis_en":"Share of Pfizer FY2025 total revenue generated from Cardinal Health","qualifier":null},"note":"카디널 헬스는 화이자의 세 번째로 큰 미국 도매상 고객이다. FY2025 화이자 총매출에서 두 자릿수 비중을 차지했다.","note_en":"Cardinal Health is Pfizer's third-largest U.S. wholesaler customer and represented a double-digit share of FY2025 total revenue.","sources":[{"stance":"confirms","publisher":"SEC EDGAR","publisher_en":"SEC EDGAR","kind":"filing","lang":"en","published_at":"2026-02-26","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm","title":"PFIZER INC 2025 사업보고서(Form 10-K)","title_en":"PFIZER INC 2025 Form 10-K","excerpt":"10-K는 2025년 카디널 헬스에서 발생한 매출이 총매출의 13%라고 공시했다.","excerpt_en":"Cardinal Health, Inc. 13%."}]},{"direction":"cost","counterparty":"삼성바이오로직스","counterparty_slug":"samsung-biologics","confidence":"mid","metric":{"type":"contract_value","unit":"KRW","as_of":"2024-01-12","basis":"2023년 7월 공시된 화이자 위탁생산 공급계약 금액","value":922750000000,"period":"2023-06-30/2029-12-31","basis_en":"Value of the Pfizer contract manufacturing supply agreement disclosed in July 2023","qualifier":null},"note":"삼성바이오로직스는 화이자 의약품을 위탁생산한다. 증권사 리서치는 2023년 7월 공시 계약의 금액과 2029년 말까지의 계약기간을 정리했다.","note_en":"Samsung Biologics provides contract manufacturing services for Pfizer. A securities research report details the value and term of the agreement disclosed in July 2023.","sources":[{"stance":"confirms","publisher":"현대차증권","publisher_en":"Hyundai Motor Securities","kind":"research","lang":"ko","published_at":"2024-01-12","url":"https://www.hmsec.com/documents/research/20240112070425593_ko.pdf","title":"삼성바이오로직스: 지속 성장, 수주 속도를 보라!","title_en":"Samsung Biologics: Watch the Pace of New Orders","excerpt":"보고서는 2023년 7월 3일 화이자 계약을 9,227.5억원, 계약 종료일을 2029년 12월 31일로 제시했다.","excerpt_en":"The report lists the July 3, 2023 Pfizer contract at KRW 922.75 billion, ending December 31, 2029."},{"stance":"confirms","publisher":"삼성바이오로직스","publisher_en":"Samsung Biologics","kind":"ir","lang":"ko","published_at":"2023-07-04","url":"https://samsungbiologics.com/kr/media/company-news/samsung-biologics-unveils-$-897-mln-manufacturing-deals-for-pfizer","title":"화이자 '1.2조' 생산 계약...삼성바이오, 글로벌 빅파마 수주 질주","title_en":"Samsung Biologics Wins KRW 1.2 Trillion of Pfizer Manufacturing Contracts","excerpt":"삼성바이오로직스는 화이자로부터 1조2,000억원 규모의 위탁생산 계약을 수주했다고 밝혔다.","excerpt_en":"Samsung Biologics said it won Pfizer contract manufacturing orders worth KRW 1.2 trillion."}]},{"direction":"cost","counterparty":"애질런트 테크놀로지스","counterparty_slug":"agilent-technologies","confidence":"mid","metric":{"type":"amount","unit":"USD","as_of":"2021-12-13","basis":"화이자 생산 사이트에 제공한 CrossLab 엔터프라이즈 서비스 매출","value":null,"period":"2021 CrossLab enterprise services deployment","basis_en":"CrossLab enterprise-services revenue from the Pfizer production site","qualifier":"confirmed_no_disclosed_value"},"note":"화이자는 24시간 생산 사이트에서 애질런트 CrossLab 전담팀을 통해 장비 유지보수, 적격성평가, 규정준수와 자산 모니터링 서비스를 이용했으며, 계약 금액과 애질런트 귀속 매출은 공개되지 않았다.","note_en":"Pfizer used a dedicated Agilent CrossLab team at a 24/7 production site for instrument maintenance, qualification, compliance, and asset monitoring, while the contract value and revenue attributable to Agilent were not disclosed.","sources":[{"stance":"confirms","publisher":"애질런트 테크놀로지스","publisher_en":"Agilent Technologies","kind":"analysis","lang":"en","published_at":"2021-12-13","url":"https://www.agilent.com/cs/library/casestudies/public/casestudy-led-crosslab-enterprise-services-pfizer-5994-2278en-agilent.pdf","title":"애질런트 제약 사례연구: 화이자","title_en":"Agilent Pharmaceutical Case Study: Pfizer","excerpt":"애질런트는 화이자에 거의 전담으로 배치된 CrossLab Services 팀을 제공했다.","excerpt_en":"Agilent provided a CrossLab Services team dedicated almost exclusively to Pfizer."}]},{"direction":"cost","counterparty":"메틀러 토레도","counterparty_slug":"mettler-toledo","confidence":"mid","metric":{"type":"amount","unit":"USD","as_of":"1999-04-01","basis":"화이자 계열사의 메틀러 토레도 검증 서비스 이용액","value":null,"period":"1999","basis_en":"Pfizer affiliates' use of Mettler-Toledo validation services","qualifier":"confirmed_no_disclosed_value"},"note":"화이자는 메틀러 토레도의 검증 서비스 자료에서 해당 서비스를 사용한 제약 제조사로 Pfizer Animal Health Canada와 Pfizer Ilaçlari가 제시됐지만, 공개된 계약 금액이 없고 오래된 관계여서 현재 매출 규모는 확인되지 않는다.","note_en":"Pfizer is identified through Pfizer Animal Health Canada and Pfizer Ilaçlari in Mettler-Toledo's validation-services material as a pharmaceutical manufacturer familiar with those services, but no contract value is disclosed and the historical evidence does not establish the current revenue contribution.","sources":[{"stance":"confirms","publisher":"메틀러 토레도","publisher_en":"Mettler-Toledo","kind":"ir","lang":"en","published_at":"1999-04-01","url":"https://www.mt.com/dam/mt_ext_files/Editorial/Generic/4/Validation_0x0002464400026a70000ba5f3_files/brochurevalidatione.pdf","title":"System Validation: A Helping Hand to Maintain Product and Process Quality","title_en":"System Validation: A Helping Hand to Maintain Product and Process Quality","excerpt":"자료는 메틀러 토레도의 검증 서비스를 이용한 제조사 명단에 Pfizer Animal Health Canada와 Pfizer Ilaçlari를 포함한다.","excerpt_en":"The following manufacturers are familiar with our validation services: Pfizer Animal Health, Canada; Pfizer Ilaçlari, Turkey."}]}]}